MedTrace Logo

Program ACTIVE II: Behavioral Depression Treatment for Type 2 Diabetes

NCT03371940 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2024-05-28

Study results available
· View outcomes & findings →

Summary

Program ACTIVE II is a depression treatment study sponsored by the National Institutes of Health, Indiana University, Ohio University and West Virginia University. The purpose of this study is to test the effectiveness of two forms of treatment for depression for adults with type 2 diabetes: talk therapy (counseling) and exercise. Both of these forms of treatment have been proven to be effective in helping people with depression alone. In this study, the investigators will test to see if both of these approaches may be more effective in helping people live depression-free compared to talk therapy, exercise or usual care alone.

Conditions

Interventions

BEHAVIORAL

Program ACTIVE Exercise

Please see the Exercise arm description above.

BEHAVIORAL

Program ACTIVE CBT

Please see the Talk Therapy arm description above.

BEHAVIORAL

Program ACTIVE

Please see the Talk Therapy + Exercise arm description above.

BEHAVIORAL

Usual Care - No intervention

Please see the Usual Care arm description above.

Sponsors & Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    collaborator NIH

  • West Virginia University

    collaborator OTHER

  • Ohio University

    collaborator OTHER

  • University of Michigan

    collaborator OTHER

  • Indiana University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-01
Primary Completion
2016-06-30
Completion
2017-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03371940 on ClinicalTrials.gov